Drug intelligence / Profile preview

VYR-2020c

Development stage: Preclinical
Lead developer: Vyripharm Biopharmaceuticals
Modality: Small Molecules

Overview

VYR-2020c is a small molecule therapeutic candidate currently in preclinical development by Vyripharm International. It is being investigated for the treatment of Post-Traumatic Stress Disorder (PTSD) and for applications related to the detection or management of cytokine storms associated with post-COVID-19 complications. As part of Vyripharm's precision medicine pipeline, the compound aims to address neuroinflammatory and immune-related pathologies, although its specific molecular targets and mechanism of action have not been publicly detailed in available pipeline documentation.

Beyond the preview

Go deeper on VYR-2020c.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VYR-2020c.

Explore the full profile